about
Twist and p53 reciprocally regulate target genes via direct interactionTaxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough StrategyPro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancerSuppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance.Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate.The Expression of Ubiquitous Mitochondrial Creatine Kinase Is Downregulated as Prostate Cancer Progression.Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.Nuclear redox imbalance affects circadian oscillation in HaCaT keratinocytes.Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancerRenal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation.Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer.PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer.Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth.Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer.Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells.A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer.Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.p300 mediates cellular resistance to doxorubicin in bladder cancer.Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer.Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.Ectonucleoside triphosphate diphosphohydrolase 6 expression in testis and testicular cancer and its implication in cisplatin resistance.Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor.Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer.P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance.
P50
Q24316412-34D680F3-DC52-4C98-BC8F-BAB4AB2D7F64Q26770247-6B4565AE-6B4C-451B-82EB-F826925E0417Q26852582-BCEE3F5F-D884-45D4-BAE2-0F4AA2BC387BQ30008838-66314837-169C-494F-B798-ED2FCCF6A734Q34775998-17CAAA2C-E72A-44AC-97C3-FE6C779EBE6EQ35164397-3DB83AE3-1A4D-4B9C-85DE-9BA6F11515A0Q36372406-A15B446F-91BA-45F0-A58B-09BF530B1399Q37866912-BD6B9CD8-DF37-4446-8AF7-62A4273B3657Q37901484-38641E18-FDF0-4912-897B-1C018480AC9BQ38091759-533E7E81-E063-40BB-BB6C-E39C2E283194Q38742577-6150F173-46A6-499D-BC16-A4784D5D971DQ38777429-74058F1C-8030-40EA-A64E-A795D2531AC8Q38803264-69D0961F-7CE3-4D9D-95B0-5DD57966FFC2Q38840477-8D52FC86-687C-4F21-AD94-9C7D749CAE90Q38869093-73CD476A-ABC1-4346-8237-F8FBAC634029Q38887592-F720D65B-3180-460D-B027-5BCA8201CD6FQ38926803-D6BBD86D-65B6-4892-A994-FC2A4D9CADD4Q38965263-709AF039-189D-42AB-BCB2-374807A8DFF3Q39000270-EBE24BD8-5CD5-48D7-AB84-32F9B3573987Q39003326-D592710E-0FC4-4115-A859-3817036D9A87Q39004481-55054197-3D5C-482F-82C6-582420AAA60AQ39024826-3C236316-E15C-431A-A4AF-8B710E356380Q39027755-2DC1FFCC-2369-4D29-9750-D7842EC19009Q39041986-552AD0B5-8015-47ED-883C-36C53F912ECAQ39130877-1F81B195-88E4-48FE-AEE5-6FEE5F89A4AAQ39181034-06E4C986-6A72-49FE-B9AE-61B54E42D2E7Q39181056-42FD88B3-D5F6-4B91-8F34-5294A695A1A1Q39197304-1B3A2B39-26C4-485E-A687-B20BF59885EFQ39345954-C79227B7-B615-4332-9ADA-4DCABA93756FQ39394737-3411CED2-70B6-49B5-8585-CECC7F8750FAQ39470619-E654322F-58D3-4460-AACA-1AB64C60BD78Q39528789-A4EBBA64-717A-49EF-A20F-9FCEDE4609B4Q39542365-7D3615F4-2AD0-4667-B945-5A6163A85AA4Q39547783-647A354B-7C92-4539-BECC-05FC401020BCQ39548876-2C8B29AF-52B9-47F8-884E-BE7586F2728AQ39553079-60FB9809-2149-462B-B8CD-F9B104C9388EQ39642888-1E96D213-B42A-4ECA-B70E-F41769F6A41CQ39666388-F3FED1EA-FC00-4669-ADCD-DF48B9790223Q39683668-EA60782B-898B-4CDC-B606-74B5A596A218Q39701578-C5344C56-39E0-49F1-BF0F-C07BACA55464
P50
description
researcher ORCID ID = 0000-0002-3306-4858
@en
wetenschapper
@nl
name
Masaki Shiota
@ast
Masaki Shiota
@en
Masaki Shiota
@es
Masaki Shiota
@nl
type
label
Masaki Shiota
@ast
Masaki Shiota
@en
Masaki Shiota
@es
Masaki Shiota
@nl
prefLabel
Masaki Shiota
@ast
Masaki Shiota
@en
Masaki Shiota
@es
Masaki Shiota
@nl
P1153
16302305300
P31
P496
0000-0002-3306-4858